Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05537766 · ClinicalTrials.gov registry record · Phase 2
Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies
A Phase 2 study, sponsored by Kite, A Gilead Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT05537766 is a Phase 2 study that was terminated before completion, run by Kite, A Gilead Company. The registered enrollment target is 19 participants.
The verdict
NCT05537766, a Phase 2 study, was terminated before completion, sponsored by Kite, A Gilead Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
Master protocol: The goal of this master clinical study is to test how well the study drug, brexucabtagene autoleucel, works in participants with rare B-cell malignancies: relapsed/refractory Waldenstrom macroglobulinemia (r/r WM) (Substudy A), r/r Richter transformation (RT) (Substudy B), r/r Burkitt lymphoma (BL) (Substudy C) and r/r hairy cell leukemia (HCL) (Substudy D).
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL Brexucabtagene Autoleucel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2022-11-01 |
| Est. Completion | 2025-01-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05537766
The ClinicalTrials.gov registry entry for NCT05537766 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kite, A Gilead Company, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT05537766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05537766 about?
NCT05537766 is a clinical study titled "Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies". Master protocol: The goal of this master clinical study is to test how well the study drug, brexucabtagene autoleucel, works in participants with rare B-cell malignancies: relapsed/refractory Waldenstrom macroglobulinemia (r/r WM) (Substudy A), r/r Richter transformation (RT) (Substudy B), r/r Burki...
What is the current status of trial NCT05537766?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2022-11-01. Estimated completion is 2025-01-27.
What interventions are being tested in trial NCT05537766?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Brexucabtagene Autoleucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT05537766?
This trial is sponsored by Kite, A Gilead Company, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.